

Michael A Curran

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9573332/publications.pdf>

Version: 2024-02-01

53
papers

5,686
citations

172207

29
h-index

223531

46
g-index

54
all docs

54
docs citations

54
times ranked

9617
citing authors

#	ARTICLE	IF	CITATIONS
1	PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 4275-4280.	3.3	1,602
2	CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. Journal of Clinical Investigation, 2006, 116, 1935-1945.	3.9	605
3	Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. JCI Insight, 2016, 1, .	2.3	356
4	Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. Nature Immunology, 2019, 20, 835-851.	7.0	277
5	Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy. Journal of Clinical Investigation, 2018, 128, 5137-5149.	3.9	269
6	Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. Clinical Cancer Research, 2017, 23, 1388-1396.	3.2	261
7	4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity. Frontiers in Oncology, 2015, 5, 117.	1.3	211
8	Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production. PLoS ONE, 2011, 6, e19499.	1.1	189
9	Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin. Journal of Experimental Medicine, 2013, 210, 743-755.	4.2	157
10	Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity. Cancer Immunology Research, 2017, 5, 676-684.	1.6	130
11	Development of Immunotherapy Combination Strategies in Cancer. Cancer Discovery, 2021, 11, 1368-1397.	7.7	130
12	Tumor Vaccines Expressing Flt3 Ligand Synergize with CTLA-4 Blockade to Reject Preimplanted Tumors. Cancer Research, 2009, 69, 7747-7755.	0.4	120
13	Immune biology of glioma associated macrophages and microglia: Functional and therapeutic implications. Neuro-Oncology, 2020, 22, 180-194.	0.6	95
14	PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8+ T-Cell-Driven Antitumor Immunity. Clinical Cancer Research, 2018, 24, 2383-2394.	3.2	84
15	Unique potential of 4-1BB agonist antibody to promote durable regression of HPV ⁺ tumors when combined with an E6/E7 peptide vaccine. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E5290-9.	3.3	79
16	Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain. Nature Communications, 2017, 8, 1447.	5.8	67
17	Activation of 4-1BB on Liver Myeloid Cells Triggers Hepatitis via an Interleukin-27-Dependent Pathway. Clinical Cancer Research, 2018, 24, 1138-1151.	3.2	63
18	TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma. , 2019, 7, 323.		59

#	ARTICLE	IF	CITATIONS
19	Opening of the Blood-Brain Barrier Using Low-Intensity Pulsed Ultrasound Enhances Responses to Immunotherapy in Preclinical Glioma Models. <i>Clinical Cancer Research</i> , 2021, 27, 4325-4337.	3.2	58
20	Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV+ oral cancer. , 2019, 7, 252.		57
21	LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	54
22	ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer. <i>Science Immunology</i> , 2022, 7, .	5.6	52
23	New Hope for Therapeutic Cancer Vaccines in the Era of Immune Checkpoint Modulation. <i>Annual Review of Medicine</i> , 2019, 70, 409-424.	5.0	50
24	Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma. <i>JCI Insight</i> , 2018, 3, .	2.3	44
25	Profiling of patients with glioma reveals the dominant immunosuppressive axis is refractory to immune function restoration. <i>JCI Insight</i> , 2020, 5, .	2.3	43
26	MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma. <i>OncImmunology</i> , 2020, 9, 1846915.	2.1	42
27	Immune checkpoint combinations from mouse to man. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 885-892.	2.0	40
28	ISA101 and nivolumab for HPV-16 ⁺ cancer: updated clinical efficacy and immune correlates of response. , 2022, 10, e004232.		38
29	Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype. <i>Cancer Immunology Research</i> , 2020, 8, 1365-1380.	1.6	37
30	Prolonged liver-specific transgene expression by a non-primate lentiviral vector. <i>Biochemical and Biophysical Research Communications</i> , 2004, 320, 998-1006.	1.0	33
31	Gene Therapy-Mediated Reprogramming Tumor Infiltrating T Cells Using IL-2 and Inhibiting NF- κ B Signaling Improves the Efficacy of Immunotherapy in a Brain Cancer Model. <i>Neurotherapeutics</i> , 2012, 9, 827-843.	2.1	33
32	Suppression of stromal-derived Dickkopf-3 (DKK3) inhibits tumor progression and prolongs survival in pancreatic ductal adenocarcinoma. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	33
33	High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege. , 2021, 9, e003246.		32
34	Hypoxia Reduction Sensitizes Refractory Cancers to Immunotherapy. <i>Annual Review of Medicine</i> , 2022, 73, 251-265.	5.0	30
35	Efficient transduction of pancreatic islets by feline immunodeficiency virus vectors ¹ . <i>Transplantation</i> , 2002, 74, 299-306.	0.5	27
36	Discovery of IACS-8803 and IACS-8779, potent agonists of stimulator of interferon genes (STING) with robust systemic antitumor efficacy. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 126640.	1.0	27

#	ARTICLE	IF	CITATIONS
37	Peripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab. Journal of Clinical Oncology, 2013, 31, 3003-3003.	0.8	26
38	A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies. Clinical Cancer Research, 2021, 27, 3050-3060.	3.2	24
39	Intratumoral Delivery of STING Agonist Results in Clinical Responses in Canine Glioblastoma. Clinical Cancer Research, 2021, 27, 5528-5535.	3.2	22
40	Mucosal HPV E6/E7 Peptide Vaccination in Combination with Immune Checkpoint Modulation Induces Regression of HPV+ Oral Cancers. Cancer Research, 2018, 78, 5327-5339.	0.4	20
41	Current Landscape and Future Directions of Biomarkers for Immunotherapy in Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1195-1207.	1.8	19
42	Tumor hypermetabolism confers resistance to immunotherapy. Seminars in Cancer Biology, 2020, 65, 155-163.	4.3	17
43	Prolonged transgene expression in murine salivary glands following non-primate lentiviral vector transduction. Molecular Therapy, 2005, 12, 137-143.	3.7	14
44	Protection of Human Pancreatic Islets Using a Lentiviral Vector Expressing Two Genes: cFLIP and GFP. Cell Transplantation, 2008, 17, 793-802.	1.2	10
45	Response to ipilimumab (Yervoy) and the TGN1412 catastrophe. Immunobiology, 2012, 217, 590-592.	0.8	10
46	mRNA Display Discovery of a Novel Programmed Death Ligand 1 (PD-L1) Binding Peptide (a Peptide Ligand) Tj ETQq0,0 0 rgBT /Overlock	1.6	10
47	Retrovirally Transferred Genes Inhibit Apoptosis in an Insulin-Secreting Cell Line: Implications for Islet Transplantation. Cell Transplantation, 2004, 13, 489-496.	1.2	9
48	EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy. , 2019, 7, 5.		7
49	Repertoire Enhancement with Adoptively Transferred Female Lymphocytes Controls the Growth of Pre-Implanted Murine Prostate Cancer. PLoS ONE, 2012, 7, e35222.	1.1	5
50	Preclinical Data Supporting Antitumor Activity of PD-1 Blockade. Cancer Journal (Sudbury, Mass), 2018, 24, 2-6.	1.0	5
51	Directed Evolution of PD-L1-Targeted Affibodies by mRNA Display. ACS Chemical Biology, 2022, 17, 1543-1555.	1.6	3
52	Editorial: Advances in Combination Tumor Immunotherapy. Frontiers in Oncology, 2015, 5, 198.	1.3	0
53	Method of long-term, recurrent, intracerebroventricular infusion of cellular therapy in mice. Journal of Neuroscience Methods, 2022, 371, 109529.	1.3	0